Table 1.
Inhibition (IC50 values) of recombinant human MAO-A and -B by virodhamine and related analogs.a
| Compounds | MAO-A | MAO-B |
|---|---|---|
| IC50 (μM) ± S.D. | IC50 (μM) ± S.D. | |
| 2-AG | >100 | 50.53 ± 0.515 |
| Noladin ether | >100 | 18.18 ± 1.45 |
| (R)-(+)-Methanandamide | >100 | 51.090 ± 1.30 |
| Oleylethanolamide | >100 | >100 |
| Anandamide | >100 | 39.98 ± 4.60 |
| Virodhamine | 38.70 ± 3.86 | 0.71 ± 0.04 |
| Clorgyline (control) | 0.004 ± 0.0005 | ND |
| Deprenyl (control) | ND | 0.049 ± 0.0036 |
| Phenelzine (control) | 0.213 ± 0.060 | 0.150 ± 0.015 |
| Safinamide (control) | 90.00 ± 2.470 | 0.060 ± 0.005 |
a
The IC50 values computed from the concentration-response inhibition curves are mean ± S.D. of triplicate observations. ND = Not determined. Phenelzine (a nonselective MAO inhibitor), deprenyl (a selective MAO-B inhibitor), safinamide (a selective MAO-B inhibitor) and clorgyline (a selective MAO-A inhibitor) were tested simultaneously as reference standards.